Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IAPP | P10997 | 4/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | ESR1 | P03372 | 4/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409944 | 0.90 | F2RL1 (0.56) | IAPPTRPV1ESR1ESR2KDM4E | |
| SCHEMBL22414097 | 0.88 | ESR1 (0.55) | IAPPTRPV1ESR1ESR2KDM4E | |
| SCHEMBL8108885 | 0.87 | ESR1 (0.62) | IAPPTRPV1ESR1ESR2KDM4E | |
| SCHEMBL1053043 | 0.86 | IAPP (0.66) | IAPPTRPV1ESR1ESR2KDM4E | |
| SCHEMBL13267781 | 0.85 | IAPP (0.61) | IAPPTRPV1ALDH1A1LMNATDP1 | |
| SCHEMBL105765 | 0.83 | TDP1 (0.62) | IAPPALDH1A1CYP1A2SLC5A1SLC5A2 | |
| Letestuianin C SCHEMBL4410123 | 0.83 | F2RL1 (0.60) | TRPV1ESR1ESR2KDM4ECYP19A1 | |
| SCHEMBL27921443 | 0.82 | IAPP (0.68) | IAPPTRPV1ESR1ESR2KDM4E | |
| SCHEMBL27639928 | 0.82 | ACHE (0.53) | IAPPTRPV1ESR1KDM4EALDH1A1 | |
| SCHEMBL24242163 | 0.82 | IAPP (0.58) | IAPPTRPV1ALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024880-B | High-temperature-resistant plastic-wood material composition and plastic-wood product | 美新科技股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117024880-A | High-temperature-resistant plastic-wood material composition and plastic-wood product | 美新科技股份有限公司 | 2023-11-10 | — | — | CN | claimed |
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-0374184-B1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE MEDICINE (US) | 1994-01-12 | — | — | EP | claimed |
| US-5216024-A | Compounds such as methyl p-hydroxypenyllactate, derivatives | BAYLOR COLLEGE OF MEDICINE (US) | 1993-06-01 | — | — | US | claimed |
| WO-1993001824-A1 | COMBINATION THERAPY USING BIOFLAVONOID COMPOUNDS WITH ANTI-CANCER DRUGS | BAYLOR COLLEGE OF MEDICINE (US) | 1993-02-04 | — | — | WO | claimed |
| EP-0374184-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES. | BAYLOR COLLEGE MEDICINE (US) | 1990-06-27 | — | — | EP | claimed |
| WO-1989000849-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1989-02-09 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20250011293-A1 | LEUKOTRIENE SYNTHESIS INHIBITORS | NAEGIS PHARMACEUTICALS INC. (CA) | 2025-01-09 | — | — | US | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| WO-1993001824-A1 | COMBINATION THERAPY USING BIOFLAVONOID COMPOUNDS WITH ANTI-CANCER DRUGS | BAYLOR COLLEGE OF MEDICINE (US) | 1993-02-04 | — | — | WO | disclosed |
| WO-1991017749-A1 | GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1991-11-28 | — | — | WO | disclosed |
| EP-0374184-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES. | BAYLOR COLLEGE MEDICINE (US) | 1990-06-27 | — | — | EP | disclosed |
| WO-1989000849-A1 | CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES | BAYLOR COLLEGE OF MEDICINE (US) | 1989-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | IAPP 2522/4885TRPV1 3969/4885ESR1 3581/4885 |
| US-20250011293-A1 | LEUKOTRIENE SYNTHESIS INHIBITORS | LTC4S, LTB4R2, LTA4H | IAPP 2392/4885TRPV1 428/4885ESR1 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.